Jérôme Munyangi1, Lucile Cornet-Vernet2, Michel Idumbo3, Chen Lu4, Pierre Lutgen5, Christian Perronne6, Nadège Ngombe7, Jacques Bianga8, Bavon Mupenda9, Paul Lalukala10, Guy Mergeai11, Dieudonné Mumba12, Melissa Towler13, Pamela Weathers13. 1. Faculté de Médecine Université de Kolwezi-Lualaba, Congo DRC. 2. Vice Présidente de La Maison de l'Artemisia(association Loi 1901), 20 rue Pierre Demours, 75017Paris, France. Electronic address: lcv@maison-artemisia.org. 3. Centre de Santé de Lubile, Maniema, Congo DRC. 4. Department of Mathematics, Worcester Polytechnic Institute, USA. 5. Association IFVB-BELHERB, Luxembourg. 6. Faculté de Médecine de Paris IDF Ouest, France. 7. Faculté de Pharmacie, Université de Kinshasa, Congo DRC. 8. Programme National Lutte Contre le Paludisme, Maniema, Congo DRC. 9. Ecole de Santé Publique Université de Kinshasa, Congo DRC. 10. Ministère Provincial de Santé Publique Maniema, Congo DRC. 11. Université de Liège, Belgium. 12. Faculté de Médecine Université de Kinshasa, Congo DRC. 13. Department of Biology and Biotechnology, Worcester Polytechnic Institute, USA.
Abstract
BACKGROUND AND OBJECTIVE: Prior small-scale clinical trials showed that Artemisia annua and Artemisia afra infusions, decoctions, capsules, or tablets were low cost, easy to use, and efficient in curing malaria infections. In a larger-scale trial in Kalima district, Democratic Republic of Congo, we aimed to show A. annua and/or A. afra infusions were superior or at least equivalent to artesunate-amodiaquine (ASAQ) against malaria. METHODS: A double blind, randomized clinical trial with 957 malaria-infected patients had two treatment arms: 472 patients for ASAQ and 471 for Artemisia (248 A. annua, 223 A. afra) remained at end of the trial. ASAQ-treated patients were treated per manufacturer posology, and Artemisia-treated patients received 1 l/d of dry leaf/twig infusions for 7 d; both arms had 28 d follow-up. Parasitemia and gametocytes were measured microscopically with results statistically compared among arms for age and gender. RESULTS: Artemisinin content of A. afra was negligible, but therapeutic responses of patients were similar to A. annua-treated patients; trophozoites cleared after 24 h, but took up to 14 d to clear in ASAQ-treated patients. D28 cure rates defined as absence of parasitemia were for pediatrics 82, 91, and 50% for A. afra, A. annua and ASAQ; while for adults cure rates were 91, 100, and 30%, respectively. Fever clearance took 48 h for ASAQ, but 24 h for Artemisia. From D14-28 no Artemisia-treated patients had microscopically detectable gametocytes, while 10 ASAQ-treated patients remained gametocyte carriers at D28. More females than males were gametocyte carriers in the ASAQ arm but were unaffected in the Artemisia arms. Hemoglobin remained constant at 11 g/dl for A. afra after D1, while for A. annua and ASAQ it decreased to 9-9.5 g/dl. Only 5.0% of Artemisia-treated patients reported adverse effects, vs. 42.8% for ASAQ. CONCLUSION: A. annua and A. afra infusions are polytherapies with better outcomes than ASAQ against malaria. In contrast to ASAQ, both Artemisias appeared to break the cycle of malaria by eliminating gametocytes. This study merits further investigation for possible inclusion of Artemisia tea infusions as an alternative for fighting and eradicating malaria.
BACKGROUND AND OBJECTIVE: Prior small-scale clinical trials showed that Artemisia annua and Artemisia afra infusions, decoctions, capsules, or tablets were low cost, easy to use, and efficient in curing malaria infections. In a larger-scale trial in Kalima district, Democratic Republic of Congo, we aimed to show A. annua and/or A. afra infusions were superior or at least equivalent to artesunate-amodiaquine (ASAQ) against malaria. METHODS: A double blind, randomized clinical trial with 957 malaria-infected patients had two treatment arms: 472 patients for ASAQ and 471 for Artemisia (248 A. annua, 223 A. afra) remained at end of the trial. ASAQ-treated patients were treated per manufacturer posology, and Artemisia-treated patients received 1 l/d of dry leaf/twig infusions for 7 d; both arms had 28 d follow-up. Parasitemia and gametocytes were measured microscopically with results statistically compared among arms for age and gender. RESULTS: Artemisinin content of A. afra was negligible, but therapeutic responses of patients were similar to A. annua-treated patients; trophozoites cleared after 24 h, but took up to 14 d to clear in ASAQ-treated patients. D28 cure rates defined as absence of parasitemia were for pediatrics 82, 91, and 50% for A. afra, A. annua and ASAQ; while for adults cure rates were 91, 100, and 30%, respectively. Fever clearance took 48 h for ASAQ, but 24 h for Artemisia. From D14-28 no Artemisia-treated patients had microscopically detectable gametocytes, while 10 ASAQ-treated patients remained gametocyte carriers at D28. More females than males were gametocyte carriers in the ASAQ arm but were unaffected in the Artemisia arms. Hemoglobin remained constant at 11 g/dl for A. afra after D1, while for A. annua and ASAQ it decreased to 9-9.5 g/dl. Only 5.0% of Artemisia-treated patients reported adverse effects, vs. 42.8% for ASAQ. CONCLUSION: A. annua and A. afra infusions are polytherapies with better outcomes than ASAQ against malaria. In contrast to ASAQ, both Artemisias appeared to break the cycle of malaria by eliminating gametocytes. This study merits further investigation for possible inclusion of Artemisia tea infusions as an alternative for fighting and eradicating malaria.
Authors: Mostafa A Elfawal; Melissa J Towler; Nicholas G Reich; Pamela J Weathers; Stephen M Rich Journal: Proc Natl Acad Sci U S A Date: 2015-01-05 Impact factor: 11.205
Authors: Christoph H Blanke; Godson B Naisabha; Mussa B Balema; Godfrey M Mbaruku; Lutz Heide; Markus S Müller Journal: Trop Doct Date: 2008-04 Impact factor: 0.731
Authors: P Moyo; M E Botha; S Nondaba; J Niemand; V J Maharaj; J N Eloff; A I Louw; L Birkholtz Journal: J Ethnopharmacol Date: 2016-03-16 Impact factor: 4.360
Authors: John Woodford; G Dennis Shanks; Paul Griffin; Stephan Chalon; James S McCarthy Journal: Am J Trop Med Hyg Date: 2018-02-08 Impact factor: 2.345
Authors: John O Suberu; Alexander P Gorka; Lauren Jacobs; Paul D Roepe; Neil Sullivan; Guy C Barker; Alexei A Lapkin Journal: PLoS One Date: 2013-11-14 Impact factor: 3.240
Authors: B M Gruessner; L Cornet-Vernet; M R Desrosiers; P Lutgen; M J Towler; P J Weathers Journal: Phytochem Rev Date: 2019-09-19 Impact factor: 5.374
Authors: Barbara C Sorkin; Adam J Kuszak; Gregory Bloss; Naomi K Fukagawa; Freddie Ann Hoffman; Mahtab Jafari; Bruce Barrett; Paula N Brown; Frederic D Bushman; Steven J Casper; Floyd H Chilton; Christopher S Coffey; Mario G Ferruzzi; D Craig Hopp; Mairead Kiely; Daniel Lakens; John B MacMillan; David O Meltzer; Marco Pahor; Jeffrey Paul; Kathleen Pritchett-Corning; Sara K Quinney; Barbara Rehermann; Kenneth D R Setchell; Nisha S Sipes; Jacqueline M Stephens; D Lansing Taylor; Hervé Tiriac; Michael A Walters; Dan Xi; Giovanna Zappalá; Guido F Pauli Journal: FASEB J Date: 2019-12-10 Impact factor: 5.834